Recalled blood pressure drugs not linked to increased short term cancer risk

September 12, 2018, British Medical Journal
Credit: CC0 Public Domain

Products containing the withdrawn blood pressure drug valsartan are not associated with a markedly increased short term risk of cancer, finds an expedited analysis published by The BMJ today.

The findings provide reassuring interim evidence about the risk of cancer in patients treated with valsartan products, but the authors say further studies are required to evaluate the risks for single cancers as well as longer term effects.

In July 2018, some valsartan products manufactured by the Chinese company Zhejiang Huahai Pharmaceuticals were suspected of having been contaminated with N-nitrosodimethylamine (NDMA), an impurity that can cause cancer.

Following the discovery, both European medical agencies and the US Food and Drug Administration (FDA) withdrew affected valsartan products from the market.

To better understand the possible consequences and help inform regulatory bodies about this potential public issue, the Danish Medicines Agency collaborated with the University of Southern Denmark to assess the association between use of potentially NDMA contaminated valsartan products and risk of cancer.

Using data from Danish health registries, they included 5,150 patients aged 40 years and over with no previous cancer who used products containing valsartan between 1 January 2012 and 30 June 2018.

Based on product analysis and dose used, patients were classified as being exposed or not exposed to NDMA and were followed from one year after entering the study, for a median of 4.6 years, during which time cases of cancer were recorded.

After taking account of age, sex, and other potentially influential factors, the researchers found that, overall, exposure to potentially NDMA contaminated valsartan products showed no association with cancer compared with exposure to valsartan products that were not contaminated with NDMA. There was also no evidence of a dose-response pattern.

However, when they analysed single cancers, they found a slightly increased (but not statistically significant) risk of colorectal cancer and uterine cancer in patients exposed to NDMA. While they cannot fully explain this, it might require further study.

More importantly, the limited follow-up means that assessment of long-term effects is not possible, and the low number of events makes interpretation of estimates for single cancer outcomes difficult.

Nevertheless, the researchers believe that their results can support regulators in their evaluation of the potential public health impact of NDMA exposure via valsartan drugs—and provide some reassurance for people who might have been exposed.

They conclude: "Our results do not imply a marked increased short term overall cancer risk in users of valsartan contaminated with NDMA. However, uncertainty persists regarding single cancer outcomes, and studies with longer follow-up are needed to assess long-term risk."

In a linked editorial, Rita Banzi and Vittorio Bertele' at the Center for Drug Regulatory Policies in Milan, Italy, say "this study alone cannot dispel doubts about the potential risk for patients in the longer term, but it helps inform decision-making around this episode."

"It also illustrates the usefulness of national registries for examining the relations between risk factors and health problems and how research can give a prompt response whenever public health concerns emerge," they add.

Regulatory actions coupled with the generation of robust evidence, they say "are the keys to responding promptly to emerging public health concerns."

Explore further: Chinese firm recalls heart drug as US, EU raise concerns

More information: Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study, www.bmj.com/content/362/bmj.k3851

Editorial: Regulatory response to contaminated valsartan, www.bmj.com/content/362/bmj.k3855

Related Stories

Chinese firm recalls heart drug as US, EU raise concerns

July 18, 2018
The Chinese manufacturer of a widely used blood pressure medication said it had launched a global recall after US and European regulators warned of contamination by a cancer-causing impurity.

FDA recalls heart medication valsartan, citing cancer concerns

July 17, 2018
The U.S. Food and Drug Administration issued a voluntary recall of several medications that contain the active ingredient valsartan, which is used to treat high blood pressure and heart failure.

European regulator launches review of recalled heart drug

August 2, 2018
The European Medicines Agency (EMA) said Thursday it is conducting a review of the health effects on patients of a widely used blood pressure medication recalled around the world last month.

Affected by the valsartan heart drug recall? here's what to do

July 19, 2018
(HealthDay)—After the U.S. Food and Drug Administration announced last week that certain brands of blood pressure medicines contained a carcinogen and were being recalled, many patients may wonder what's next for their ...

More problems found in Chinese-made heart medications

August 6, 2018
Two more Chinese drugmakers have announced that a blood-pressure medication they exported to Taiwan contained a potentially cancer-causing impurity, a month after the same problem at another Chinese manufacturer prompted ...

Valsartan cuts microalbuminuria in impaired glucose tolerance

February 9, 2017
(HealthDay)—For patients with impaired glucose tolerance (IGT), valsartan is associated with reduced incidence of microalbuminuria, according to a study published online Jan. 17 in Diabetes, Obesity and Metabolism.

Recommended for you

Probiotic use may reduce antibiotic prescriptions, researchers say

September 14, 2018
Use of probiotics is linked to reduced need for antibiotic treatment in infants and children, according to a review of studies that probed the benefits of probiotics, say researchers in the U.S., England and the Netherlands.

Recalled blood pressure drugs not linked to increased short term cancer risk

September 12, 2018
Products containing the withdrawn blood pressure drug valsartan are not associated with a markedly increased short term risk of cancer, finds an expedited analysis published by The BMJ today.

Sugar pills relieve pain for chronic pain patients

September 12, 2018
Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology. And the pills will reduce their pain as effectively as any powerful drug on the market, according to ...

A new approach for finding Alzheimer's treatments

September 11, 2018
Considering what little progress has been made finding drugs to treat Alzheimer's disease, Maikel Rheinstädter decided to come at the problem from a totally different angle—perhaps the solution lay not with the peptide ...

One in four older adults prescribed a benzodiazepine goes on to risky long-term use

September 10, 2018
They may start as well-intentioned efforts to calm anxiety, improve sleep or ease depression. But prescriptions for sedatives known as benzodiazepines may lead to long-term use among one in four older adults who receive them, ...

Clinical need absent, unclear in nearly 30 percent of outpatient opioid prescriptions

September 10, 2018
Nearly 30 percent of outpatient opioid prescriptions in the United States lack documented clinical reasons that justify the use of these potent drugs, according to a national analysis of physician visit records conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.